Neurocognitive Dysfunction After Anesthesia in Patients With Recent Concussion
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Amy L Amsbaugh
- Phone Number: 507-538-7538
- Email: amsbaugh.amy@mayo.edu
Study Contact Backup
- Name: Brenda Anderson
- Phone Number: 507-255-7157
- Email: anderson.brenda@mayo.edu
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic in Rochester
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or Female >16 years of age with a recent concussion (<10 weeks) from planned procedure under anesthesia.
Exclusion Criteria:
- Neurologic history including history of severe cognitive disease, disorder, or delay, attention disorder, moderate to severe TBI history, neurovascular order or trauma.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Concussion Group
Subjects diagnosed with concussion defined as a clinician-diagnosed disease by the International Classification of Diseases (ICD)-10 due to a head injury with a Glasgow Coma Score ≥13 undergoing a planned surgery/anesthetic standard of care will undergo neurocognitive testing pre and post surgery/anesthetic.
|
A comprehensive assessment of neuropsychometric measures to evaluate cognitive functioning.
|
|
Experimental: Matched Subjects Group
Matched subjects without concussion undergoing a planned surgery/anesthetic standard of care, matching for procedural type, sex, age ± 2 years, and adherence to the exclusion criteria will undergo neurocognitive testing pre and post surgery/anesthetic.
|
A comprehensive assessment of neuropsychometric measures to evaluate cognitive functioning.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Wide Range Achievement Test Fourth Edition, WRAT-4
Time Frame: Pre-anesthetic to one week Post-anesthetic
|
Change in WRAT-4
|
Pre-anesthetic to one week Post-anesthetic
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Numeric Pain Scale 0-10
Time Frame: Post-operatively to hospital discharge, up to 10 days.
|
Difference in numeric pain scale between the concussion and non-concussion group.
Patients verbally select a value that is in line with the intensity of pain they have experienced in the last 24 hours.
Pain Scale is recorded "0" = no pain, "10" = the most pain imaginable.
|
Post-operatively to hospital discharge, up to 10 days.
|
|
Oral morphine equivalent of consumed opioids
Time Frame: Post-operatively to hospital discharge, up to 10 days.
|
Difference of post-operative opioid use between the concussion and non-concussion group
|
Post-operatively to hospital discharge, up to 10 days.
|
|
Length of hospital stay
Time Frame: Post-operatively to hospital discharge, up to 30 days.
|
Difference between the concussion and non-concussion group
|
Post-operatively to hospital discharge, up to 30 days.
|
|
Cognitive Deficits identified by NeuroPsychometric Cognitive Testing
Time Frame: Pre-anesthetic to one week Post-anesthetic
|
Difference between the concussion and non-concussion group.
|
Pre-anesthetic to one week Post-anesthetic
|
|
Sport Concussion Assessment Tool - 5th edition, SCAT-5
Time Frame: Pre-anesthetic to one week Post-anesthetic
|
The SCAT5 is a standardized tool for evaluating concussions designed for use by physicians and licensed medical professionals.
Difference in SCAT5 scores between the concussion and non-concussion group.
SCAT5 scores the number of symptoms (0-22) present and the severity of symptoms (0-132).
|
Pre-anesthetic to one week Post-anesthetic
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Arnoley S Abcejo, MD, Mayo Clinic
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Injuries, Traumatic
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Mental Disorders
- Wounds and Injuries
- Neurocognitive Disorders
- Cognition Disorders
- Craniocerebral Trauma
- Trauma, Nervous System
- Head Injuries, Closed
- Wounds, Nonpenetrating
- Brain Injuries
- Cognitive Dysfunction
- Brain Concussion
Other Study ID Numbers
Other Study ID Numbers
- 18-006578
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.